Thursday, 31 March 2011

NHS needs to face its responsibilities regarding Sativex

Source The MS Trust:
Despite approval as a treatment for spasticity, people with MS continue to have difficulty accessing Sativex.


In June 2010 the Medicines and Healthcare products Regulatory Agency (MHRA) licensed Sativex, a cannabis based oral spray, for use as an add-on treatment for MS-related spasticity when people have shown inadequate response to other symptomatic treatments or found their side effects intolerable.   Read more here.